230 related articles for article (PubMed ID: 1778314)
1. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques.
Gupta RK; Saxena SN; Sharma SB; Ahuja S
Dev Biol Stand; 1991; 73():205-22. PubMed ID: 1778314
[TBL] [Abstract][Full Text] [Related]
2. Comparison of toxicities of acellular pertussis vaccine with whole cell pertussis vaccine in experimental animals.
Sato Y; Sato H
Dev Biol Stand; 1991; 73():251-62. PubMed ID: 1778317
[TBL] [Abstract][Full Text] [Related]
3. Effect of heptakis (2,6-0-dimethyl)beta-cyclodextrin on cell growth and the production of pertussis toxin and filamentous hemagglutinin in Bordetella pertussis.
Suzuki Y; Imaizumi A; Ginnaga A; Sato H; Sato Y
Dev Biol Stand; 1985; 61():89-92. PubMed ID: 2872134
[TBL] [Abstract][Full Text] [Related]
4. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers.
Sato Y; Sato H
Tokai J Exp Clin Med; 1988; 13 Suppl():79-88. PubMed ID: 2908530
[TBL] [Abstract][Full Text] [Related]
5. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin.
Ginnaga A; Morokuma K; Aihara K; Sakou M; Imaizumi A; Suzuki Y; Sato H; Sato Y; Ueda K; Kuno-Sakai H
Tokai J Exp Clin Med; 1988; 13 Suppl():59-69. PubMed ID: 2908528
[TBL] [Abstract][Full Text] [Related]
6. A novel bivalent acellular pertussis vaccine based on the 69 kDa protein and FHA.
Novotny P; Chubb AP; Cownley K; Charles IG
Dev Biol Stand; 1991; 73():243-9. PubMed ID: 1778316
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the protective effects of the pertussis acellular vaccine with the component vaccine, which have different amounts of fimbriae, against the experimental aerosol infection of mice with Bordetella pertussis.
Morokuma K; Ginnaga A; Nishihara T; Tsunoda S; Furukawa M; Aihara K; Sakoh M
Dev Biol Stand; 1991; 73():223-32. PubMed ID: 1685713
[TBL] [Abstract][Full Text] [Related]
8. Production and purification of Bordetella pertussis toxin.
Ju CL; Sheu GC; Cheng Y; Lu CH
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1997 May; 30(2):72-83. PubMed ID: 10592813
[TBL] [Abstract][Full Text] [Related]
9. Collaborative study for the standardisation of the histamine sensitizing test in mice and the CHO cell-based assay for the residual toxicity testing of acellular pertussis vaccines.
Xing D; Maes A; Behr-Gross ME; Costanzo A; Daas A; Buchheit KH
Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):51-63. PubMed ID: 20223190
[TBL] [Abstract][Full Text] [Related]
10. Assay of pertussis vaccine reactivity factors by measurement of the paw swelling response, endotoxin and histamine-sensitizing factor.
Vuolo AM; Lustigman B
Biologicals; 1993 Mar; 21(1):45-52. PubMed ID: 8217117
[TBL] [Abstract][Full Text] [Related]
11. Protective immunogenicity of synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
Askelöf P; Rodmalm K; Wrangsell G; Larsson U; Svenson SB; Cowell JL; Undén A; Bartfai T
Dev Biol Stand; 1991; 73():111-20. PubMed ID: 1778305
[TBL] [Abstract][Full Text] [Related]
12. Optimization of immunization schedule to standardize antibody response in mice to pertussis vaccines.
Tiru M; Jäätmaa E; Gillenius P; Askelöf P
Dev Biol Stand; 1985; 61():469-75. PubMed ID: 2872128
[TBL] [Abstract][Full Text] [Related]
13. Comparative biological activities of acellular pertussis vaccines produced by Kitasato.
Watanabe M; Izumiya K; Sato T; Yoshino K; Nakagawa N; Ohoishi M; Hoshino M
Kitasato Arch Exp Med; 1991 Apr; 64(1):31-42. PubMed ID: 1798236
[TBL] [Abstract][Full Text] [Related]
14. Collaborative study on test systems to assess toxicity of whole cell pertussis vaccine.
van Straaten-van de Kappelle I; van der Gun JW; Marsman FR; Hendriksen CF; van de Donk HJ
Biologicals; 1997 Mar; 25(1):41-57. PubMed ID: 9167008
[TBL] [Abstract][Full Text] [Related]
15. Antibody responses after vaccination and disease against leukocytosis promoting factor, filamentous hemagglutinin, lipopolysaccharide and a protein binding to complement-fixing antibodies induced during whooping cough.
Winsnes R; Lønnes T; Møgster B; Berdal BP
Dev Biol Stand; 1985; 61():353-65. PubMed ID: 2872124
[TBL] [Abstract][Full Text] [Related]
16. Further evaluation of the pertussis component vaccine produced by apoceruloplasmin affinity chromatography.
Ginnaga A; Morokuma K; Furukawa S; Shigaki T; Katsuki N; Aihara K; Oka T; Sakoh M; Tamura C; Imaizumi A
Dev Biol Stand; 1991; 73():233-41. PubMed ID: 1778315
[TBL] [Abstract][Full Text] [Related]
17. Engineering bacterial toxin for the development of new vaccine against pertussis.
Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
[TBL] [Abstract][Full Text] [Related]
18. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
[TBL] [Abstract][Full Text] [Related]
19. Development of acellular pertussis vaccines.
Sato Y; Sato H
Biologicals; 1999 Jun; 27(2):61-9. PubMed ID: 10600185
[TBL] [Abstract][Full Text] [Related]
20. [Properties of an acellular preparation of Bordetella pertussis and its analysis after centrifugation in saccharose gradient].
Letowska I; Kaczurba E; Schiller B
Med Dosw Mikrobiol; 1993; 45(3):289-94. PubMed ID: 8189799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
